Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Knight Therapeutics Inc T.GUD

Alternate Symbol(s):  KHTRF

Knight Therapeutics Inc. is a specialty pharmaceutical company. The Company’s principal business activity is developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select... see more

TSX:GUD - Post Discussion

Knight Therapeutics Inc > Product Pipeline ...
View:
Post by MrMugsy on Sep 02, 2021 1:16pm

Product Pipeline ...

Looking at the Product Pipeline PDF, there was one detail I forgot to mention ... 

In the "partnering" column, some products are identified as "OWN."  So we know we own them outright - at lease in certain geographies.  That's where limited information comes our way.

In the above mentioned PDF, we own 10 of these such drugs on the list.
In addition to the present geographies where the  products are preparing to launch, maybe some of these could also launch in other geographies in the future - we just don't know those details - if there are additional details to follow.

For example, we know we are launching KARFIB in Argentina at this time and we know we own the rights.  What we don't know from looking at this PDF is ... could we prepare that drug for launch in Brazil, Columbi, Mexico or other LATAM geographies in the future.  Just something to keep in mind going forward.

---------------

also ...

I spoke with Samira recently and I asked about what "beefing up disclosure" might mean.

It seems to be related to forecasting ... providing additional colour for the future on sales numbers.  She indicated that Knight would need some external assistance in order to make that kind of information available - but - they are working towards improved disclosure.

For what it's worth - hope that helps.

----------------

Heading in the right direction - things seem to be coming together nicely (for my liking).

I think it is safe to say we are picking up speed and showing signs of growth.  Let's see if they can create some momentum over the next few quarters by stringing some quarterly growth together.  That's really where we're at now ... finally !  And we can't forget about efficency gain over the next two quarters - we are still expecting that as well.
Comment by Snowballgrowth on Sep 02, 2021 4:23pm
I added again today. Just too cheap to ignore here with a long term horizon and the growth we saw during the last quarter. Next quarters should good be good also with Exelon sales consolidated. We will see. This is not a recommandation but look very interesting for long term. IMO
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities